Graham Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Graham Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,288	Closed	-$466K	–	1228
2025 Q2	$466K	Sell	20,288 -6,136	-23%	-$152K	0.01%	854
2025 Q1	$766K	Buy	+26,424	New	+$844K	0.01%	637
2024 Q2	–	Sell	-6,339	Closed	-$278K	–	1026
2024 Q1	$278K	Buy	+6,339	New	+$327K	0.01%	813
2022 Q3	–	Sell	-60,386	Closed	-$2.1M	–	1049
2022 Q2	$2.1M	Buy	60,386 +29,718	+97%	+$1.06M	0.09%	196
2022 Q1	$1.1M	Buy	+30,668	New	+$870K	0.04%	274

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Graham Capital Management's AMPH Position: Q3 2025 in Review

Graham Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2025, closing a stake of 20,288 shares — an estimated $466K sold.

Graham Capital Management first reported a position in AMPH in Q1 2022 and held it in 5 quarters. The position peaked at $2.1M in Q2 2022. 243 funds tracked by Wall St. Rank hold AMPH as of Q3 2025.

Graham Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Graham Capital Management sold 20,288 Amphastar Pharmaceuticals shares in Q3 2025, an estimated $466K.
Graham Capital Management first reported a position in Amphastar Pharmaceuticals in Q1 2022 and held it in 5 quarters.
Graham Capital Management's Amphastar Pharmaceuticals position peaked at $2.1M in Q2 2022.
243 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.